Table 2.

Antiproliferative properties of the newly synthesised compounds

Comp.	Conc. (μM)	Growth inhibition; % ± SEM [calculated IC50 value; μM]a
		UPCI-SCC-131	UPCI-SCC-154	HeLa	SiHa	C33-A	A2780	MCF-7	MDA-MB-231	T47D	NIH/3T3
4	10	99.80 ± 0.36	97.29 ± 1.10	85.11 ± 2.44	97.44 ± 0.54	99.57 ± 0.61	96.90 ± 1.52	99.52 ± 0.51	99.97 ± 0.71	99.68 ± 0.74	101.1 ± 0.67
	30	99.88 ± 0.39	97.81 ± 0.65	99.43 ± 0.28	99.28 ± 0.42	99.55 ± 0.39	100.5 ± 0.22	99.83 ± 0.44	94.64 ± 2.26	99.92 ± 0.71	100.9 ± 0.71
		[3.17]b	[5.15]	[4.45]	[3.31]	[3.60]	[6.24]	[3.70]	[3.97]	[3.46]	[2.79]
5	10	99.54 ± 0.33	96.40 ± 0.89	75.07 ± 3.73	98.98 ± 0.26	93.88 ± 2.56	94.85 ± 2.13	99.70 ± 0.43	97.15 ± 1.46	100.2 ± 0.28	100.8 ± 0.16
	30	99.94 ± 0.44	100.3 ± 0.82	99.65 ± 0.25	99.97 ± 0.42	100.0 ± 0.23	100.9 ± 0.18	100.6 ± 0.31	98.57 ± 0.89	101.3 ± 0.47	100.3 ± 0.25
		[2.38]	[4.50]	[6.99]	[2.30]	[3.75]	[6.70]	[3.35]	[4.07]	[3.47]	[2.74]
9	10	63.42 ± 1.41	–c	–	–	–	47.23 ± 2.75	21.29 ± 2.79	–	57.45 ± 3.15	–
	30	99.35 ± 0.27	99.82 ± 1.48	97.59 ± 0.73	96.49 ± 1.24	97.85 ± 0.32	98.99 ± 0.41	93.08 ± 1.60	99.03 ± 0.73	93.77 ± 0.55	96.55 ± 0.86
		[5.30]	[13.49]	[12.90]	[13.79]	[13.32]	[11.74]	[13.67]	[23.49]	[7.20]	[20.44]
13	10	29.88 ± 1.21	–	–	–	–	–	–	–	26.68 ± 1.95	–
	30	97.02 ± 0.43	75.94 ± 1.93	95.69 ± 0.69	92.90 ± 0.85	96.31 ± 0.46	97.77 ± 0.35	84.92 ± 2.54	95.56 ± 0.67	89.82 ± 0.68	89.76 ± 0.49
		[12.28]	[21.51]	[14.34]	[13.72]	[14.51]	[23.75]	[14.75]	[25.81]	[13.58]	[19.27]
17	10	26.48 ± 1.70	–	–	–	–	–	–	–	–	n. d.d
	30	45.31 ± 1.84	20.26 ± 2.69	–	–	–	–	–	–	27.12 ± 2.93
11	10	20.86 ± 1.67	–	–	–	–	–	–	–	24.70 ± 1.70	n. d.
	30	62.45 ± 1.40	38.56 ± 2.60	23.80 ± 2.11	30.22 ± 2.99	40.26 ± 0.95	21.91 ± 2.63	37.06 ± 0.72	–	58.96 ± 1.38
15	10	24.60 ± 1.39	–	–	–	–	–	–	–	39.07 ± 2.01	n. d.
	30	60.22 ± 1.32	34.66 ± 1.36	27.44 ± 1.57	–	26.94 ± 0.84	49.39 ± 2.06	–	–	58.50 ± 0.80
19	10	–	34.27 ± 2.80	30.96 ± 1.11	23.24 ± 1.36	28.08 ± 1.39	–	31.84 ± 2.47	–	59.44 ± 2.44	n. d.
	30	40.98 ± 2.94	48.81 ± 2.15	48.89 ± 0.90	40.30 ± 2.00	34.69 ± 1.70	28.51 ± 2.35	40.60 ± 1.71	–	62.41 ± 1.70
10	10	39.82 ± 1.36	–	–	–	21.96 ± 1.84	–	–	–	–	n. d.
	30	72.93 ± 1.70	24.32 ± 2.84	21.53 ± 2.99	–	27.25 ± 1.85	64.25 ± 2.65	35.85 ± 3.30	–	61.09 ± 1.06
14	10	48.75 ± 1.50	–	–	–	26.86 ± 2.13	–	–	–	22.60 ± 1.33	–
	30	97.29 ± 1.38	87.05 ± 1.16	99.14 ± 0.37	92.97 ± 1.37	101.1 ± 0.24	100.3 ± 0.22	89.98 ± 2.88	98.22 ± 0.39	85.98 ± 1.51	52.71 ± 2.87
		[10.92]	[11.38]	[12.22]	[11.75]	[10.93]	[21.46]	[14.37]	[17.59]	[13.85]	[29.64]
18	10	46.39 ± 1.19	–	–	–	–	–	–	–	–	n. d.
	30	64.55 ± 1.29	–	–	–	20.25 ± 1.01	–	–	–	–
12	10	49.38 ± 2.06	–	–	–	–	–	–	–	31.38 ± 1.55	–
	30	90.01 ± 1.15	75.46 ± 1.84	96.39 ± 1.88	94.83 ± 1.48	97.68 ± 0.85	97.14 ± 0.55	90.19 ± 1.61	84.01 ± 2.61	75.02 ± 1.65	48.34 ± 1.65
		[14.18]	[29.83]	[13.62]	[14.12]	[13.63]	[28.46]	[16.42]	[24.46]	[16.97]	[30.85]
16	10	49.45 ± 2.27	–	–	–	–	–	–	–	23.63 ± 1.22	n. d.
	30	67.44 ± 1.11	31.55 ± 2.41	31.83 ± 2.27	–	59.09 ± 0.69	67.27 ± 3.04	–	–	64.48 ± 1.60
20	10	48.25 ± 1.46	30.97 ± 2.54	–	–	27.94 ± 0.89	–	28.24 ± 1.66	–	66.09 ± 0.76	n. d.
	30	61.12 ± 1.32	28.72 ± 1.11	–	–	26.53 ± 1.06	–	22.21 ± 2.78	–	68.56 ± 1.81
CISe	10	95.63 ± 1.49	87.40 ± 1.72	42.61 ± 2.33	88.64 ± 0.50	85.98 ± 1.05	83.6 ± 1.2	66.91 ± 1.81	–	40.41 ± 1.25	76.74 ± 1.26
	30	95.09 ± 1.57	92.72 ± 1.67	99.93 ± 0.26	90.18 ± 1.78	98.66 ± 0.21	95.0 ± 0.3	96.80 ± 0.35	71.47 ± 1.20	56.84 ± 1.16	96.90 ± 0.25
		[1.22]	[1.29]	[12.43]	[7.84]	[4.13]	[1.30]	[5.78]	[19.13]	[19.24]	[4.73]

^aMean value from two independent measurements with five parallel wells; standard deviation <20%.

^bIC₅₀ values have been calculated if the growth inhibition value of the compound at 30 μM concentration is higher than 75%.

^cInhibition values <20% are not presented.

^dNot determined.

^eCisplatin.